Catherine M. Szyman
CIK 1438538 · Chief Executive Officer · last filed 2026-06-12
Catherine M. Szyman is a Chief Executive Officer who has filed 120 SEC Form 4 insider transactions across 5 companies since 2008. Across all open-market trades the lifetime net is −$46.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.9M across reported positions. 13 SEC filings were submitted jointly with MEDTRONIC INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
52 DISCOVERY
IRVINE, CA 92618
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MASIMO CORP (MASI) Delisted | CEO | 8,674 | $179.95 | $1.56M | $0 | 5 | 2026-03-16 |
| Inari Medical, Inc. (NARI) Delisted | Director | 0 | $79.97 | $0 | $533.7K | 8 | 2025-02-19 |
| EW | CVP, Critical Care | 81,287 | $90.09 | $7.32M | -$42.15M | 88 | 2024-09-03 |
| OM | Director | 1,640 | $4.17 | $6.8K | $0 | 4 | 2023-05-31 |
| MDT | SrVP & Pres Diabetes | 36,521 | $96.59 | $3.53M | -$4.95M | 10 | 2014-03-21 |
Recent Filings
120 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | — | Disp (D) | −7,605 | -$1.37M | |
| 2026-03-16 | MASIMO CORP (MASI) Delisted | Mixed | +1,032 | -$187.6K | EDGAR |
| 2026-03-10 | MASIMO CORP (MASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-02-13 | MASIMO CORP (MASI) Delisted | Mixed | +6,573 | $1.48M | EDGAR |
| 2025-03-13 | MASIMO CORP (MASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-19 | Inari Medical, Inc. (NARI) Delisted | Mixed | −22,429 | $0 | EDGAR |
| 2025-02-14 | MASIMO CORP (MASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-09-03 | EW | Mixed | +5,380 | -$386.9K | EDGAR |
| 2024-07-08 | EW | Tax (F) | −258 | -$23.8K | EDGAR |
| 2024-05-31 | Inari Medical, Inc. (NARI) Delisted | Grant (A) | +4,126 | $175.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.